Gatehouse Bio
Waltham, US · Founded 2017 · Delaware corporation · 1 known investors
Gatehouse Bio develops AI-powered therapeutics for pulmonary, cardiac, neurological, and autoimmune diseases by decoding small RNAs using their Code-Breaker platform to design precision medicine treatments.
Founders & leadership
Gatehouse Bio was founded in 2017 by David W. Salzman.
DW
David W. SalzmaninFounder
NF
Neal FosterNamed on SEC filing
DW
David W. Salzman, Ph.D.Named on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$5.4M disclosed across 1 round · 2020
▶$5.4MraisedJan 2021 · 28 investors · BiotechnologyRule 506(b)
▶$5.4MraisedJan 2021 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Neal FosterExecutive Officer, Director
- David W. Salzman, Ph.D.Executive Officer, Director
- Offering amount
- $5.4M
- Amount sold
- $5.4M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapGate Bio5 shared keywordsGate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment. The company operates in the drug discovery and development space.
Syndeio Biosciences5 shared keywordsSyndeio Biosciences is a synapse-focused biotech developing precision neurotherapeutics for neuropsychiatric, mental health, and cognitive disorders such as depression and Alzheimer's. Its proprietary Boost Platform models synapse pharmacology, and its pipeline includes NMDA receptor positive allosteric modulators (zelquistinel and apimostinel) in Phase 2 clinical trials.
Precision BioSciences4 shared keywordsPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Gate2Brain4 shared keywordsGate2Brain develops therapeutics designed to cross biological barriers, particularly the blood-brain barrier, using a proprietary peptide-based technology platform. The company focuses on biotech drug development for conditions requiring brain delivery.
Companies competing with Gatehouse Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Gatehouse Bio do?
- Gatehouse Bio develops AI-powered therapeutics for pulmonary, cardiac, neurological, and autoimmune diseases by decoding small RNAs using their Code-Breaker platform to design precision medicine treatments.
- Who founded Gatehouse Bio?
- Gatehouse Bio was founded by David W. Salzman in 2017.
- Who are Gatehouse Bio's investors?
- Gatehouse Bio's investors include Claritas Capital.
- How much funding has Gatehouse Bio raised?
- Gatehouse Bio has disclosed $5.4M raised across 1 round.
- Where is Gatehouse Bio headquartered?
- Gatehouse Bio is headquartered in Waltham, US.